Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page ) r' q! L5 x1 z' V# z! H
, B) b% D% q7 l0 H* T2 E) i7 R
$ o; A. b* z. [ J# |Sub-category:
3 _! q1 Z H$ A0 s! n. r+ OMolecular Targets
1 K V/ C4 O3 k! |3 y- S- Y0 z7 b- ]9 l% A8 `2 ^' D
$ X. V$ I& C4 I+ Z; d
Category:+ ?+ o$ k1 Z& A* u( d
Tumor Biology + G5 }$ u% H" h) Z# ~
) y }2 G3 O1 ]0 @- i% L
7 C- U" K+ ]4 O9 H
Meeting:( _% j- G) A9 J; ?
2011 ASCO Annual Meeting " ~6 `, d" N0 ]1 E2 \# q
7 S' Z) ?( H' D# R4 w; k
6 D6 c- K' N8 r
Session Type and Session Title:
7 M- o8 }2 I O" F: f1 }! vPoster Discussion Session, Tumor Biology
8 n* p; |7 ?* c4 r. ^! Y6 f' u
3 O7 |; J2 I& a k7 | |, V% T0 T
. H' e* c/ n5 c" B! F5 y, HAbstract No:
7 R, m8 n5 Q$ Y10517
' K1 J" Q1 }1 d# ?' E, }
' r$ ]2 M* J7 P, X' S& ? P6 x, {2 d4 h7 N, \/ H+ K
Citation:9 D; U8 O# _* B/ A* Q
J Clin Oncol 29: 2011 (suppl; abstr 10517) 7 A; M5 [# v5 _# {
/ x8 f3 T5 v4 @3 ]4 X* h7 U: D, F
' ]+ }( \8 J" Q5 ]Author(s):# ]2 E3 O4 X4 k" G7 g; O7 _4 u
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China ; G" C* x" q/ o
: S! Q3 P0 ^- N! ]* @7 o7 a0 j7 M2 |
; F0 b# K' C/ d8 e* g8 |$ c0 }; c2 B* G+ q' n$ s
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
/ t# u J/ h3 \* A
5 A2 o8 s. [: o- bAbstract Disclosures
( B# j: ?9 _9 K/ }
6 \ N0 V! n) b* ^+ M% z4 g; f' T0 VAbstract:" q) r0 C r9 S' S: m) z% o4 z; K
; S2 M. A: q" q" Y% A( [) s8 _$ P5 g X- H& K( a2 ~% c, p" t9 _1 w, S
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.& O& s. J" R" u) O* b
; s1 K5 {- i/ l1 [$ x3 _$ s3 Q+ f! ~
) q: r7 H3 h$ `/ O' @' P7 |8 K5 J |
妈妈肺癌成功跨越9年啦！我们想把一
讲述者：c.c整理者：pear2016年3月，妈妈确诊为肺腺癌3B期。九年间，我们走过一代、三
肺癌晚期要配合放疗吗
这次去了中肿，有教授说我爸这种情况化疗免疫搭配放疗可能取得根治性效果，还是能算在
80岁老人抗癌五年 EGFR基因检测到第2
时间线
2021年7月9日-14日在上海肺科医院
出院小结为：
1、右肺下叶恶性肿瘤:右肺下
经过7天的等待时间 基因报告出来了
爸爸目前有一个阳性突变 是 E..del19很感恩！真的！其他全是阴性 不知道具体好不好 真
患者家属深度参与，真正让肺癌患者看
转载自：希思科基金会一直以来，国内外各类医学指南在为临床医生提供权威诊疗依据的同
. z9 o' B ]( b6 z) T! F9 V/ L5 R
显身卡
